{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:31:04Z","timestamp":1793255464365,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Common genetic variants in\n                      <jats:italic toggle=\"yes\">CYP3A4<\/jats:italic>\n                      together only explain a limited amount of the variability in tacrolimus clearance. This cross-sectional study aimed to explore the extent to which pharmacokinetic variability can be explained by methylation of the\n                      <jats:italic toggle=\"yes\">CYP3A4<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Residual tissue material from liver biopsies routinely collected 6 months post-transplantation was used. Inclusion criteria were tacrolimus once daily (Advagraf) in a steady state (ie, no dose change in the previous 3 days); assessment of tacrolimus pharmacokinetics within 3 weeks of the biopsy; and no documented episode of rejection for at least 3 months prior. Patients and liver donor tissue were genotyped. Only patients in which the patient and the donor had a genotype that did not express the CYP3A5 protein were included. The liver biopsy tissue material was then analyzed using an Illumina Infinium MethylationEPIC array.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 28 patients who met the inclusion criteria, 23 passed the quality control assessment required for the methylation analysis. Increased methylation of 1 of the 10 methylation probes within the\n                      <jats:italic toggle=\"yes\">CYP3A4<\/jats:italic>\n                      gene region (cg19046783) was positively correlated (Spearman correlation coefficient, 0.52) with the dose-normalized area under the concentration versus time curve (AUC)\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). When quantified using univariate linear regression, this probe explained 18% of the variation in the dose-normalized AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      . Interestingly, cg19046783 had the lowest mean methylation and highest biological variation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Increased methylation of 1 of the 10 methylation probes within the\n                      <jats:italic toggle=\"yes\">CYP3A4<\/jats:italic>\n                      gene region (cg19046783) was positively correlated with increased dose-normalized AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      , which explained 18% of the variation in the dose-normalized AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      using univariate linear regression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001351","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T19:00:33Z","timestamp":1752087633000},"page":"e76-e81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of CYP3A4 Methylation on Tacrolimus Pharmacokinetics"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-9273","authenticated-orcid":false,"given":"Karel K. M.","family":"Koudijs","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Etsouli","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza L.","family":"Vallerga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"},{"name":"Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian N.","family":"Ruijter","sequence":"additional","affiliation":[{"name":"Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands; and"},{"name":"Department of Gastroenterology, Hepatology and Transplantation Center, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minneke J.","family":"Coenraad","sequence":"additional","affiliation":[{"name":"Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands; and"},{"name":"Department of Gastroenterology, Hepatology and Transplantation Center, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"},{"name":"Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/dmd.118.084772","article-title":"Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites","volume":"47","author":"Guo","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.3390\/jcm11216320","article-title":"Comparison of tacrolimus intra-patient variability during 6-12 Months after kidney transplantation between CYP3A5 expressers and nonexpressers","volume":"11","author":"Nuchjumroon","year":"2022","journal-title":"J Clin Med"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","article-title":"Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients","volume":"72","author":"Moes","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients","volume":"31","author":"Press","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cpt.3077","article-title":"Tacrolimus pharmacokinetics is associated with gut microbiota diversity in kidney transplant patients: results from a pilot cross-sectional study","volume":"115","author":"Degraeve","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype","volume":"50","author":"Waring","year":"2020","journal-title":"Xenobiotica"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/phar.1362","article-title":"Epigenetic changes in gene expression for drug-metabolizing enzymes and transporters","volume":"34","author":"Kim","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","article-title":"CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation Consortium, college of American Pathologists, Dutch pharmacogenetics working group of the royal Dutch pharmacists association, European society for pharmacogenomics and personalized therapy, and pharmacogenomics knowledgebase","volume":"25","author":"Pratt","year":"2023","journal-title":"J Mol Diagn"},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/pharmaceutics13111960","article-title":"Variability of tacrolimus trough concentration in liver transplant patients: which role of inflammation?","volume":"13","author":"Chavant","year":"2021","journal-title":"Pharmaceutics"},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcp.21224","article-title":"DNA methylation: the nuts and bolts of repression","volume":"213","author":"Miranda","year":"2007","journal-title":"J Cel Physiol"},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/dmd.115.068726","article-title":"Dynamics of cytosine methylation in the proximal promoters of CYP3A4 and CYP3A7 in pediatric and prenatal livers","volume":"44","author":"Vyhlidal","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2164-7-181","article-title":"Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation","volume":"7","author":"Dannenberg","year":"2006","journal-title":"BMC Genomics"},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.biochi.2012.07.013","article-title":"DNA methylation dynamics in the hepatic CYP3A4 gene promoter","volume":"94","author":"Kacevska","year":"2012","journal-title":"Biochimie"},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.13459","article-title":"Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure","volume":"84","author":"Brussee","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-022-29792-6","article-title":"DNA methylation signature of chronic low-grade inflammation and its role in cardio-respiratory diseases","volume":"13","author":"Wielscher","year":"2022","journal-title":"Nat Commun"},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(97)00043-4","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:14:59Z","timestamp":1786047299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001351","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2025-01-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}